Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelets: the universal killer?

Andrew D Blann1

  • 1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK. a.blann@bham.ac.uk

Biochimica Et Biophysica Acta
|April 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Von Willebrand factor antigen levels predict major adverse cardiovascular events in patients with carotid stenosis of the ICARAS study.

Atherosclerosis·2019
Same author

Net Clinical Benefit of Edoxaban for Stroke, Mortality, and Bleeding Risk: Modeling Projections for a European Population.

JACC. Clinical electrophysiology·2018
Same author

Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2016
Same author

Relationship between renal function and circulating microparticles, soluble P-selectin and E-selectin levels in atrial fibrillation.

Journal of thrombosis and thrombolysis·2016
Same author

Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease.

Journal of the American College of Cardiology·2016
Same author

Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation.

Journal of thrombosis and thrombolysis·2016

Overactive platelets contribute to life-threatening thrombotic events like heart attack and stroke. Minimizing platelet activation is crucial for preventing these occlusive vascular conditions.

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Pathophysiology

Background:

  • Cessation of heartbeat, often fatal, results from myocardial oxygen and glucose deprivation.
  • This deprivation is primarily caused by platelet-rich thrombus blocking coronary arteries or arterioles.
  • Similar thrombotic processes underlie stroke, a debilitating and frequently fatal neurological event.

Purpose of the Study:

  • To highlight the central role of overactive platelets in major life-threatening occlusive events.
  • To underscore the need for novel strategies to minimize inappropriate platelet activation.
  • To identify new tools and treatments for managing thrombotic conditions.

Main Methods:

  • Review of existing literature on cardiovascular disease and stroke pathophysiology.

Related Experiment Videos

  • Analysis of the role of platelet aggregation in thrombus formation.
  • Identification of therapeutic targets for modulating platelet activity.

    • Main Results:

    • Platelet-rich thrombus formation is a principal cause of arterial occlusion in cardiovascular disease and stroke.
    • Overactive platelets are identified as the key culprit in inappropriate thrombotic events.
    • The study emphasizes the link between platelet activation and major vascular pathologies.

    Conclusions:

    • Minimizing platelet activation is a critical therapeutic strategy for preventing occlusive thrombotic events.
    • Development of new tools and treatments targeting platelet activation is urgently needed.
    • Understanding platelet hyperactivity is key to advancing treatments for cardiovascular and cerebrovascular diseases.